GNMX stock forecast
Our latest prediction for Aevi Genomic Medicine, Inc.'s stock price was made on the Aug. 15, 2018 when the stock price was at 1.12$.
In the short term (2weeks), GNMX's stock price should outperform the market by 6.33%. During that period the price should oscillate between -7.25% and +14.09%.
In the medium term (3months), GNMX's stock price should outperform the market by 11.94%. During that period the price should oscillate between -14.54% and +41.03%.Get email alerts
Create a solid portfolio with GNMX
About Aevi Genomic Medicine, Inc.
Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engages in finding treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.28$ per share.
The book value per share is 0.26$
Three months stock forecastAug. 15, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|